European Nuclear Medicine Guide
1. Cicone F, Russo E, Carpaneto A, Prior JO, Delaloye AB, Scopinaro F, et al. Follicular lymphoma at relapse after rituximab containing regimens: comparison of time to event intervals prior to and after 90Y-ibritumomab-tiuxetan. Haematological Oncology 2011;29:131–8. https://doi.org/10.1002/hon.968.
2. Buchegger F, Prior JO, Allenbach G, Baechler S, Kosinski M, Helg C, et al. Longer Intervals Between Haematopoietic Stem Cell Transplantation and Subsequent 90Y-Ibritumomab Radioimmunotherapy May Correlate With Better Tolerance. Clinical Nuclear Medicine 2012;37:960–964. https://doi.org/10.1097/RLU.0b013e318251e3af.
3. Cooney-Qualter E, Krailo M, Angiolillo A, Fawwaz RA, Wiseman G, Harrison L, et al. A phase I study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20-positive non-Hodgkin’s lymphoma: a Children’s Oncology Group study. Clin Cancer Res 2007;13:5652s–60s. https://doi.org/10.1158/1078-0432.CCR-07-1060.
4. Aricò D, Grana CM, Vanazzi A, Ferrari M, Mallia A, Sansovini M, et al. The role of dosimetry in the high activity 90Y-ibritumomab tiuxetan regimens: Two cases of abnormal biodistribution. Cancer Biotherapy & Radiopharmaceuticals 2009;24:271–5. https://doi.org/10.1089/cbr.2008.0541.
5. Tennvall J, Fischer M, Bischof Delaloye A, Bombardieri E, Bodei L, Giammarile F, et al. EANM procedure guideline for radio-immunotherapy for B-cell lymphoma with 90Y-radiolabelled ibritumomab tiuxetan (Zevalin). European Journal of Nuclear Medicine and Molecular Imaging 2007;34:616–622. https://doi.org/10.1007/s00259-007-0372-y.
6. Fisher DR, Shen S, Meredith RF. MIRD Dose Estimate Report No. 20: Radiation Absorbed-Dose Estimates for 111In- and 90Y-Ibritumomab Tiuxetan. Journal of Nuclear Medicine 2009;50:644–652. https://doi.org/10.2967/jnumed.108.057331.
7. Assié K, Dieudonné A, Gardin I, Buvat I, Tilly H, Vera P. Comparison Between 2D and 3D Dosimetry Protocols in 90 Y-Ibritumomab Tiuxetan Radioimmunotherapy of Patients with Non-Hodgkin’s Lymphoma. Cancer Biotherapy & Radiopharmaceuticals 2008;23:53–64. https://doi.org/10.1089/cbr.2007.372.
8. Ferrer L, Malek E, Bodet-Milin C, Legouill S, Prangère T, Robu D, et al. Comparisons of dosimetric approaches for fractionated radioimmunotherapy of non-Hodgkin lymphoma. The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society Of. 2012;56:529–37. PMID: 23358406
9. Wiseman GA, Kornmehl E, Leigh B, Erwin WD, Podoloff DA, Spies S, et al. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin’s lymphoma: combined data from 4 clinical trials. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine 2003;44:465–74. PMID: 12621016.
10. Dewaraja YK, Schipper MJ, Shen J, Smith LB, Murgic J, Savas H, et al. Tumour-Absorbed Dose Predicts Progression-Free Survival Following 131I-Tositumomab Radioimmunotherapy. Journal of Nuclear Medicine 2014;55:1047–1053. https://doi.org/10.2967/jnumed.113.136044.
11. Cicone F, D’Arienzo M, Carpaneto A, Russo E, Coniglio A, Bischof Delaloye A, et al. Quantification of Dose Nonuniformities by Voxel-Based Dosimetry in Patients Receiving 90 Y-Ibritumomab-Tiuxetan. Cancer Biotherapy & Radiopharmaceuticals 2013;28:98–107. https://doi.org/10.1089/cbr.2012.1299.
12. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, et al. Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma. Journal of Clinical Oncology 2002;20:2453–2463. https://doi.org/10.1200/JCO.2002.11.076.
13. Cremonesi M, Ferrari M, Grana CM, Vanazzi A, Stabin M, Bartolomei M, et al. High-dose radioimmunotherapy with 90Y-ibritumomab tiuxetan: comparative dosimetric study for tailored treatment. J Nucl Med 2007;48:1871–9. https://doi.org/10.2967/jnumed.107.044016.
14. Scholz CW, Pinto A, Linkesch W, Lindén O, Viardot A, Keller U, et al. 90 Yttrium-Ibritumomab-Tiuxetan as First-Line Treatment for Follicular Lymphoma: 30 Months of Follow-Up Data From an International Multicenter Phase II Clinical Trial. Journal of Clinical Oncology 2013;31:308–313. https://doi.org/10.1200/JCO.2011.41.1553.
15. Illidge TM, Mayes S, Pettengell R, Bates AT, Bayne M, Radford JA, et al. Fractionated 90Y-Ibritumomab Tiuxetan Radioimmunotherapy As an Initial Therapy of Follicular Lymphoma: An International Phase II Study in Patients Requiring Treatment According to GELF/BNLI Criteria. Journal of Clinical Oncology 2014;32:212–218. https://doi.org/10.1200/JCO.2013.50.3110.
16. Witzig TE, White CA, Gordon LI, Wiseman GA, Emmanouilides C, Murray JL, et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin’s lymphoma. J Clin Oncol 2003;21:1263–70. https://doi.org/10.1200/JCO.2003.08.043.
17. European Medicines Agency. (2024, July 8). Public statement: Zevalin (ibritumomab tiuxetan) – Cessation of validity of the marketing authorisation in the European Union. https://www.ema.europa.eu/en/documents/public-statement/public-statement-zevalin-cessation-validity-marketing-authorisation-european-union_en.pdf
18. Wirth A, Mikhaeel NG, Aleman BMP, Pinnix CC, Constine LS, Ricardi U, et al. Involved Site Radiation Therapy in Adult Lymphomas: An Overview of International Lymphoma Radiation Oncology Group Guidelines. International Journal of Radiation Oncology*Biology*Physics [Internet]. 2020 Aug [cited 2025 Oct 20];107(5):909–33. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0360301620309433